References du Glossaire

ABDEL-WAHAB O et FIGUEROA, ME. <em>Interpreting new molecular genetics in myelodysplastic syndromes</em>. American Society of Hematology Education Book; Hematology 2012. 2012(1):56-64.

BARZI A et SEKERES M. <em>Myelodysplastic syndromes: a practical approach to diagnosis and treatment</em>. Cleveland Clinic Journal of Medicine. 2010;77(1):37-44.

BEJAR R, STEVENSON K, ABDEL-WAHAB O, et collab. <em>Clinical effect of point mutations in myelodysplastic syndromes.</em> The New England Journal of Medicine. 2011;364(26):24 962 506.

GREENBERG P, Cox C, LEBEAU MM, et collab. <em>International scoring system for evaluating prognosis in myelodysplastic syndromes.</em> Blood. 1997;89(6):2079-2088.

GREENBERG PL, TUECHLER H, SCHANZ J, et collab. <em>Revised international prognostic scoring system for myelodysplastic syndromes.</em> Blood. 2012;120(12):2454-2465.

HOWLADER N, NOONE AM, KRAPCHO M, et collab. (éd.) <em>SEER Cancer Statistics Review, </em>1975-2010, National Cancer Institute. Bethesda, MD, d’après la soumission de novembre 2010, affichée sur le site Web de SEER, 2013.

KORETH J, PIDALA J, PEREZ WS, et collab. <em>Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an International Collaborative Decision Analysis.</em> Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;20;31(21):2662-2670.

LIESVELD JL, LICHTMAN MA. <em>Myelodysplastic syndromes, clonal cytopenias and oligoblastic myelogenous leukemia.</em> In: Lichtman MA, Kipps TJ, Seligsohn U, et collab. (éd.). Williams Hematology. 8e éd. McGraw-Hill Professional; 2010: chap 88.

LINDSLEY RC, EBERT BL. <em>Molecular pathophysiology of myelodysplastic syndromes.</em> Annual Review of Pathology. 2013;8(1):21-47. List AF. New therapeutics for myelodysplastic syndromes. Leukemia Research. 2012;36(12):1470-1474.

SCHANZ J, TUCHLER H, SLOE F, et collab. <em>New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.</em> Journal of Clinical Oncology. 2012; 30:820-829.

SEKERES MA. <em>The epidemiology of myelodysplastic syndromes. </em>Hematology/Oncology Clinics of North America. 2010;24(2):287-294.

VOSO MT, FENU S, LATAGLIATA R, et collab. <em>Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. </em>Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(21):2671-2677.